Tenon Medical Q3 revenue up 32% but misses estimates

Tenon Medical

13/11/2025 21:27

Overview

Tenon Medical Q3 revenue grows 32% yr/yr to $1.17 mln, missing analysts' expectations

Net loss for Q3 2025 was $3.3 mln, slightly higher than Q3 2024

Company raised $2.85 mln in PIPE financing post-Q3 to fund growth

Outlook

Company plans SImmetry+ alpha launch in Q4 2025

Tenon Medical aims for sustained growth via portfolio diversification and commercial expansion

Company raised $2.85 mln in PIPE financing to fund growth initiatives

Result Drivers

PROCEDURE VOLUME - Record Catamaran procedure volumes and SImmetry sales drove revenue growth, per CEO Steve Foster

PORTFOLIO EXPANSION - Integration of SiVantage acquisition expanded product offerings and commercial reach

GROSS MARGIN IMPROVEMENT - Higher revenue helped absorb fixed overhead costs, improving gross margin to 66%

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$1.17 mln
$1.37 mln (2 Analysts)
Q3 Net Income
-$3.34 mln
Q3 Operating Expenses
$4.17 mln
Q3 Operating Income
-$3.39 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Tenon Medical Inc is $2.88, about 55.1% above its November 12 closing price of $1.29

Press Release: ID:nACS9LrZ0a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)